Combination Drugs
Executive Summary
For pharmaceutical companies, combination products look like a relatively low-risk way to create a new product, one that can also extend the life of a patent-expiring compound. They can be good business: according to IMS Health, combination drugs introduced in the past four years generated almost $10 billion in sales in the US in 2003. More and more combination products are in pharma's pipeline and coming to market. Some of these drugs do well, but many don't. Why?
You may also be interested in...
The Vioxx Withdrawal: Can the Industry Avoid the Whirlpool?
The Vioxx withdrawal is one of those seminal events that, because of the players involved--the industry's largest companies, some of their most valuable drugs, both the European and American regulatory structures--holds up a mirror to an entire industry. Given the record breaking valuation slides, the market is taking a very critical look at the industry's strategies; so should the people who run it.
The Vioxx Withdrawal: Can the Industry Avoid the Whirlpool?
The Vioxx withdrawal is one of those seminal events that, because of the players involved--the industry's largest companies, some of their most valuable drugs, both the European and American regulatory structures--holds up a mirror to an entire industry. Given the record breaking valuation slides, the market is taking a very critical look at the industry's strategies; so should the people who run it.
Canary in the Coalmine: Pfizer R&D
In an interview, Pfizer's head of R&D, John LaMattina, discusses R&D's position as the part of the company most vulnerable to cuts in response to weakening sales. Among other issues, LaMattina discusses Pfizer's increasing interest in large molecules, specialist markets and combination products, and the role external research will play in filling a pipeline facing significant near-term generic pressures. He also details Pfizer's advantages of scale, particularly in developing portfolios of products in individual disease areas for sale to major customers interested in large discounted, disease-managed product packages.